title: Pharmacokinetics of adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation.
abstract: We investigated the pharmacokinetics of cytotoxic anticancer agents administered under anhepatic conditions. Beagle dogs underwent either a sham operation consisting of laparotomy only (control group, n = 11) or a laparotomy and total hepatectomy under venovenous bypass (anhepatic group, n = 12). Each dog received a bolus intravenous injection of either Adriamycin (1 mg/kg) or cisplatin (1 mg/kg). The plasma and urine concentrations of each drug were measured at intervals for up to 2 h after drug injection. The dogs given Adriamycin were then sacrificed to determine tissue drug concentrations in the liver (controls only), spleen, kidney, heart, lung, skeletal muscle and small intestine. The control and anhepatic groups showed similar Adriamycin profiles during the initial 5 min after drug injection. However, subsequently, the plasma Adriamycin concentrations remained persistently higher in the anhepatic dogs than in the controls, yielding a two-fold elevation of the mean area under the concentration-time curve in the anhepatic group (P < 0.01 vs controls). The renal clearance values did not significantly differ between the two groups. The tissue Adriamycin concentrations in all measured organs, excluding the liver, were higher in the anhepatic group than in the controls. In a second set of experiments with cisplatin, the plasma platinum concentrations did not significantly differ between the two groups throughout the time course. However, the renal clearance of platinum in the anhepatic dogs showed a fourfold increase compared with that in the controls (P < 0.01). These pharmacokinetic data suggest that Adriamycin carries the risk of increased systemic toxicities, while cisplatin may be associated with increased renal toxicity when administered during the anhepatic period of liver transplantation.
authors.affiliation: First Department of Surgery, Kobe University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ku
authors.forename: N
authors.initials: N
authors.lastname: Kusunoki
authors.forename: T
authors.initials: T
authors.lastname: Kitagawa
authors.forename: I
authors.initials: I
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Fukumoto
authors.forename: T
authors.initials: T
authors.lastname: Iwasaki
authors.forename: M
authors.initials: M
authors.lastname: Tominaga
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Kuroda
authors.forename: Y
authors.initials: Y
authors.lastname: Tanigawara
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002945:Cisplatin / Q000008:administration & dosage / Q000097:blood / Q000652:urine; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000652:urine; D005260:Female; D006439:Hemodynamics; D006498:Hepatectomy; D016031:Liver Transplantation; D008297:Male; D014018:Tissue Distribution
chemical_list: D004317:Doxorubicin; D002945:Cisplatin